Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 6/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PDE6D | O43924 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4317700 | 0.88 | HIF1A (0.35) | CYP2C19TDP1PDE1CKDM4E | |
| SCHEMBL4317703 | 0.88 | HIF1A (0.35) | CYP2C19TDP1PDE1CKDM4E | |
| SCHEMBL4317698 | 0.88 | HIF1A (0.35) | CYP2C19TDP1PDE1CKDM4E | |
| SCHEMBL5067454 | 0.85 | KIF11 (0.38) | KIF11PDE1CKDM4E | |
| SCHEMBL5062358 | 0.85 | KIF11 (0.38) | KIF11PDE1CKDM4E | |
| SCHEMBL5067455 | 0.85 | KIF11 (0.38) | KIF11PDE1CKDM4E | |
| SCHEMBL5604623 | 0.82 | TDP1 (0.40) | KIF11CYP3A4MAP1LC3BCYP2C19KCNH2 | |
| SCHEMBL4522589 | 0.80 | KIF11 (0.48) | KIF11CYP3A4MAP1LC3BCYP2C19KCNH2 | |
| SCHEMBL4518988 | 0.79 | KIF11 (0.51) | KIF11CYP3A4MAP1LC3BCYP2C19KCNH2 | |
| SCHEMBL4286034 | 0.78 | KIF11 (0.65) | KIF11CYP3A4MAP1LC3BCYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124641-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2009-05-14 | — | — | US | disclosed |
| US-20090124641-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2009-05-14 | — | — | US | disclosed |
| US-20090124641-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2009-05-14 | — | — | US | disclosed |
| EP-1855685-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006078598-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124641-A1 | Mitotic Kinesin Inhibitors | KIF5B, KIF2C, KIF18B | KIF11 12/4885CYP3A4 4803/4885MAP1LC3B 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.